PFA
ARKG icon

Pathway Financial Advisers’s ARK Genomic Revolution ETF ARKG Stock Holding History

Pathway Financial Advisers’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-351
Closed -$9.71K – 175
2025
Q3 		$9.71K Buy
+351
New +$8.87K ﹤0.01% 340

Other funds holding ARKG

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Pathway Financial Advisers's ARKG Position: Q4 2025 in Review

Pathway Financial Advisers sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2025, closing a stake of 351 shares — an estimated $9.71K sold.

Pathway Financial Advisers first reported a position in ARKG in Q3 2025 and held it in 1 quarter. The position peaked at $9.71K in Q3 2025. 238 funds tracked by Wall St. Rank hold ARKG as of Q4 2025.

  • Pathway Financial Advisers reported no remaining ARK Genomic Revolution ETF position as of Q4 2025 after selling out during the quarter.
  • Pathway Financial Advisers sold 351 ARK Genomic Revolution ETF shares in Q4 2025, an estimated $9.71K.
  • Pathway Financial Advisers first reported a position in ARK Genomic Revolution ETF in Q3 2025 and held it in 1 quarter.
  • Pathway Financial Advisers's ARK Genomic Revolution ETF position peaked at $9.71K in Q3 2025.
  • 238 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2025.

Based on Pathway Financial Advisers's 13F filing for Q4 2025, filed 6 Feb 2026.